What is Nanozora used for?

Nanozora is indicated for Rheumatoid arthritis.

Nanozora is developed by Taisho Pharmaceutical Co., Ltd..

What development phase is Nanozora in?

Nanozora is FDA-approved (marketed).

What is the generic name of Nanozora?

OZORALIZUMAB is the generic (nonproprietary) name of Nanozora.

Last reviewed 2026-04-20 · How we verify

Nanozora (OZORALIZUMAB)

Taisho Pharmaceutical Co., Ltd. · FDA-approved active Monoclonal antibody Quality 17/100

At a glance

Generic name	OZORALIZUMAB
Sponsor	Taisho Pharmaceutical Co., Ltd.
Target	Tumor necrosis factor
Modality	Monoclonal antibody
Therapeutic area	Oncology
Phase	FDA-approved

Approved indications

Rheumatoid arthritis

Common side effects

No common side effects on file.

Key clinical trials

An Extension Study of TS-152 in Subjects with Rheumatoid Arthritis (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Nanozora CI brief — competitive landscape report
Nanozora updates RSS · CI watch RSS
Taisho Pharmaceutical Co., Ltd. portfolio CI